Abstract
Aim: Study aims to assess amylase, lipase of patients with Type 2 diabetes under different types of treatments. Materials & methods: Patients'treatment modalities including insulin, metformin, pioglitazone, sodium-glucose co-transporter-2 inhibitors, insulin secretagogues, dipeptidyl peptidase-4inhibitors and glucagon like peptide-1receptor agonists were compared. Results: There was no difference in amylase and lipase levels between dipeptidyl peptidase-4 inhibitor users and non-users (p=0.2, p=0.3, respectively) and glucagon like peptide-1 analog users and non-users (p=0.1, p=0.7, respectively). Patients who use insulin secretagogues had significantly higher amylase, lipase (77.2±39.8 vs 69.5±33.0, p=0.038 and 47.2±33.2 vs 39.6±26.8, p=0.01, respectively) and patients on basal insulin had lower amylase levels (69.9±37.7 vs 77.2±33.7, p=0.014). Conclusion: Incretin-based therapies showed no difference in amylase and lipase levels whereas there was increase with secretagogues and decrease with basal insulin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
